TY - JOUR
T1 - Modification of the lipidic and coagulative pattern in postmenopause women
T2 - Effect of hormone replacement therapy
AU - Evola, G.
AU - Novo, G.
AU - Amoroso, G.
AU - Guttilla, D.
AU - Lo Coco, L.
AU - Guagliardo, M.
AU - Lupo, A.
AU - Averna, M. R.
AU - Giambanco, V.
AU - Miller, V.
AU - Novo, S.
PY - 2010/8
Y1 - 2010/8
N2 - Aim. We evaluated the changes of lipidic and coagulative pattern during menopause and the influence of hormone replacement therapy (HRT) on these parameters. Methods. We considered 158 patients divided into 2 groups: Group I consisted of 127 women in physiological/surgical menopause and Group II of 31 women with childbearing potential. Subsequently, we considered a group III formed of 34 patients from menopausal women (group I) who underwent three months of HRT. We evaluated total-cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), triglycerides (TG), lipoprotein (a) (Lpa), fibrinogen, antithrombin III (ATIII), factor VII (FVII) and tissue factor pathway inhibitor (TFPI). Results. We found a worse lipid profile in the postmenopausal group compared to controls (TC 243.8±29.7 vs 217.9±32.7 mg%, P=0.002; TG 121.5±68.4 vs 88.6±53.0 mg%, P=0.039; LDL-C 163.0±27.9 vs 136.2±29.6 mg%, P=0.004; HDL-C 60.9±14.9 vs 64.1±14.6 mg%, P=ns). With regard to the coagulative pattern, fibrinogen was significantly higher in the post-menopausal group (fibrinogen: 273.3±67.4 vs 243.8±39.5 mg%, P=0.013; ATIII 112.2±11.7 vs 117.5±12.7% %, P=0.059; FVII 121.6*11.3 vs 117.6±10.8 mg%, P=ns; TFPI activity 2.5±2.3 vs 2.1±1.1 V/mL, P=ns; TFPI antigen 120±38 vs 127±39 U/mL, P=ns). Comparing the same parameters, before and after three months of HRT, in patients of Group III we observed a significant improvement of TC and TG levels (TC from 232.3±42.7 to 215.2±37.6 mg%, P=0.0001; TG from 103.7±56.8 to 95.0±44.3 mg%, P=0.059; HDL-C from 62.3±12.9 to 63.6±12.6 mg%, P=ns; LDL-C from 149.3±38.7 to 132.6±34.5 mg%, P=0.0001). The following changes were observed with regard to coagulative parameters: fibrinogen from 270.9±69.4 to 253.2±56.2 mg%, P=0.07; ATIII from 113.5±11.4 to 110.8±13.2 mg%, P=0.198; FVII from 108.6±18.0 to 104.4±17.5 mg%, 0.014. TFPI activity from 2.6*2.3 to 2.3*1.4 U/ml, P=ns; TFPI antigen from 68*13 to 87*22 U/mL, P=0.001. Conclusions. Our data confirm the presence of an alteration in lipidic and coagulative pattern in post menopausal women and positive changes after HRT.
AB - Aim. We evaluated the changes of lipidic and coagulative pattern during menopause and the influence of hormone replacement therapy (HRT) on these parameters. Methods. We considered 158 patients divided into 2 groups: Group I consisted of 127 women in physiological/surgical menopause and Group II of 31 women with childbearing potential. Subsequently, we considered a group III formed of 34 patients from menopausal women (group I) who underwent three months of HRT. We evaluated total-cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), triglycerides (TG), lipoprotein (a) (Lpa), fibrinogen, antithrombin III (ATIII), factor VII (FVII) and tissue factor pathway inhibitor (TFPI). Results. We found a worse lipid profile in the postmenopausal group compared to controls (TC 243.8±29.7 vs 217.9±32.7 mg%, P=0.002; TG 121.5±68.4 vs 88.6±53.0 mg%, P=0.039; LDL-C 163.0±27.9 vs 136.2±29.6 mg%, P=0.004; HDL-C 60.9±14.9 vs 64.1±14.6 mg%, P=ns). With regard to the coagulative pattern, fibrinogen was significantly higher in the post-menopausal group (fibrinogen: 273.3±67.4 vs 243.8±39.5 mg%, P=0.013; ATIII 112.2±11.7 vs 117.5±12.7% %, P=0.059; FVII 121.6*11.3 vs 117.6±10.8 mg%, P=ns; TFPI activity 2.5±2.3 vs 2.1±1.1 V/mL, P=ns; TFPI antigen 120±38 vs 127±39 U/mL, P=ns). Comparing the same parameters, before and after three months of HRT, in patients of Group III we observed a significant improvement of TC and TG levels (TC from 232.3±42.7 to 215.2±37.6 mg%, P=0.0001; TG from 103.7±56.8 to 95.0±44.3 mg%, P=0.059; HDL-C from 62.3±12.9 to 63.6±12.6 mg%, P=ns; LDL-C from 149.3±38.7 to 132.6±34.5 mg%, P=0.0001). The following changes were observed with regard to coagulative parameters: fibrinogen from 270.9±69.4 to 253.2±56.2 mg%, P=0.07; ATIII from 113.5±11.4 to 110.8±13.2 mg%, P=0.198; FVII from 108.6±18.0 to 104.4±17.5 mg%, 0.014. TFPI activity from 2.6*2.3 to 2.3*1.4 U/ml, P=ns; TFPI antigen from 68*13 to 87*22 U/mL, P=0.001. Conclusions. Our data confirm the presence of an alteration in lipidic and coagulative pattern in post menopausal women and positive changes after HRT.
KW - Hormone replacement therapy
KW - Menopause
KW - Tissue factor pathway inhibitor
UR - http://www.scopus.com/inward/record.url?scp=77958600636&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958600636&partnerID=8YFLogxK
M3 - Article
C2 - 20671654
AN - SCOPUS:77958600636
SN - 0392-9590
VL - 29
SP - 355
EP - 361
JO - International Angiology
JF - International Angiology
IS - 4
ER -